Dose-Finding Study of CD07805/47 Topical Gel in Subjects With Erythematotelangiectatic Rosacea - Full Text View

Sponsor:	Galderma
Information provided by:	Galderma
ClinicalTrials.gov Identifier:	NCT00989014

Purpose

This is a randomized, double-blind, parallel-group, vehicle-controlled, dose-finding study to investigate the pharmacodynamics and the safety of three dosages of CD07805/47 topical gel (0.07%, 0.18%, and 0.50%), after a single application in subjects with a clinical diagnosis of stable moderate to severe erythematotelangiectatic rosacea. Subjects will be randomized in a 1:1:1:1 ratio to receive either one of three CD07805/47 topical gel concentrations (0.07%, 0.18%, or 0.50%) or Vehicle Gel. All subjects will be treated with a single application (once daily dosing for one day) of study medication.

Condition	Intervention	Phase
Erythematotelangiectatic Rosacea	Drug: CD07805/47	Phase II

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Dose Comparison, Parallel Assignment, Safety Study
Official Title:	Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Dose-Finding Study Investigating the Pharmacodynamics and Safety of Three Concentrations of CD07805/47 Topical Gel (0.07%, 0.18%, and 0.50%), Applied in Subjects With Moderate to Severe Erythematotelangiectatic Rosacea

Resource links provided by NLM:

MedlinePlus related topics: Rosacea

U.S. FDA Resources

Further study details as provided by Galderma:

Primary Outcome Measures:

Clinician's Erythema Assessment [ Time Frame: Baseline and every hour for 12 hours following application ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Patient's Self Assessment [ Time Frame: Baseline and every hour for 12 hours following application ] [ Designated as safety issue: No ]

Estimated Enrollment:	112
Study Start Date:	September 2009
Estimated Study Completion Date:	December 2009
Estimated Primary Completion Date:	November 2009 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
CD07805/47 0.5% Topical Gel: Experimental 0.5% Topical Gel	Drug: CD07805/47 0.5% Topical Gel
CD07805/47 0.18% Topical Gel: Experimental 0.18% Topical Gel	Drug: CD07805/47 0.18% Topical Gel
CD07805/47 0.07% Topical Gel: Experimental 0.07% Topical Gel	Drug: CD07805/47 0.07% Topical Gel
CD07805/47 Vehicle Topical Gel: Placebo Comparator Vehicle Topical Gel	Drug: CD07805/47 Vehicle Topical Gel

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Male or female who is at least 18 years of age.
Clinical diagnosis of stable moderate to severe erythematotelangiectatic rosacea.
CEA (clinician's erythema assessment) score greater than or equal to 3 at Screening and on Treatment visit at baseline.
PSA (patient self assessment) score of greater than or equal to 3 at Screening and on Treatment visit at baseline.
Presence of 2 or fewer inflammatory facial lesions.

Exclusion Criteria:

History of Raynaud's Syndrome, glaucoma, orthostatic hypotension, thromboangiitis obliterans, cerebral or coronary insufficiency, or depression.
History of refractive surgery such as photorefractive keratectomy.
The subject is being treated with monoamine oxidase (MAO) inhibitor, anti-depressants, barbiturates, opiates, sedatives, systemic anesthetics, alpha-agonists, beta blockers, antihypertensive agents, cardiac glycosides, or systemic anticoagulants.
The subject is currently enrolled in an investigational drug or device study or participated in such a study in the past 3 months prior to enrollment and is still in the exclusion period on the day of the Treatment visit.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00989014

Contacts

Contact: Matthew Leoni, MD

matthew.leoni@galderma.com

Locations

United States, Arkansas
Burke Pharmaceutical Research	Recruiting
Hot Springs, Arkansas, United States, 71913
Contact: Tim Dugan 501-620-4449
Principal Investigator: Dowling Stough, MD
United States, Pennsylvania
Philadephia Institute of Dermatology	Recruiting
Fort Washington, Pennsylvania, United States, 19034
Contact: Donna Keenan 215-836-7900
Principal Investigator: Andrew Pollack, MD
United States, Texas
Derm Research, Inc	Recruiting
Austin, Texas, United States, 78759
Contact: Amber Boykin 512-349-9889
Principal Investigator: Michael Jarratt, MD
J&S Studies	Recruiting
College Station, Texas, United States, 77845
Contact: Jeremy Scott 979-774-5933
Principal Investigator: Terry Jones, MD
United States, Virginia
The Education & Research Foundation	Recruiting
Lynchburg, Virginia, United States, 24501
Contact: Sue Foster 434-847-8400
Principal Investigator: Kappa Meadows, MD

Sponsors and Collaborators

Galderma

Investigators

Study Director:

Michael Graeber, MD

Galderma

More Information

No publications provided

Responsible Party:	Head of Global Clinical Project Management and US Development ( Michael Graeber MD )
Study ID Numbers:	RD.06.SPR.18144
Study First Received:	September 30, 2009
Last Updated:	October 1, 2009
ClinicalTrials.gov Identifier:	NCT00989014 History of Changes
Health Authority:	United States: Food and Drug Administration

Keywords provided by Galderma:

Erythematotelangiectatic
Rosacea

Additional relevant MeSH terms:

Rosacea
Skin Diseases

ClinicalTrials.gov processed this record on November 20, 2009